WHO warns giving up on efforts to control Covid-19 would be ‘dangerous’
White House Chief of Staff Mark Meadows seemed to indicate the Trump administration has concluded containment of the virus is not possible.
Related Articles
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Pharmalittle: We’re reading about plans for generic Wegovy, cough syrup warnings, and more
Biocon is developing a generic version of Novo Nordisk’s Wegovy and is prepared to conduct a clinical trial next year if needed.
Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more
BIO’s about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and…
Pharmalittle: We’re reading about Lilly’s Zepbound for sleep apnea, the FDA budget, and more
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
Pharmalittle: We’re reading about CVS and Humira biosimilars, Schumer’s broken insulin promise, and more
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week…
Pharmalittle: We’re reading about a J&J cough syrup, a Pfizer and Moderna patent suit, and more
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps
Colorado lawmakers are abandoning a bill that would have required a new state board — chartered with setting caps for the cost of medicines — to…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal…
Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s…